# US 2026/0060997 A1 · Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060997 A1
- Document ID: US20260060997A1
- Status: Published application
- Kind: A1
- Application number: 19/074,905
- Filed: 2025-03-10
- Published: 2026-03-05
- Earliest claimed: 2016-11-08
- Assignees: PT. Sahabat Lingkungan Hidup
- Applicants: PT. Sahabat Lingkungan Hidup
- Inventors: Peter Sugita; Wiwiek Widyastuti Budiliantono; Aurelia Maxine Sugita
- Web page: https://patentgrep.com/patent/US20260060997A1

## CPC

- A61K 31/716: Glucans
- A61K 36/074: Ganoderma
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using β-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising β-1,3/1,6-D-glucan are also provided.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A method of treating ST-elevation myocardial infarction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, wherein the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, has been substantially isolated from Ganoderma lucidum mycelium.

### Claim 39

A method of treating ST-elevation myocardial infarction in a subject in need thereof, comprising administering to the subject a therapeutically amount of a pharmaceutical composition comprising β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, wherein the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, has been substantially isolated from Ganoderma lucidum mycelium.

### Claim 40 (depends on 38)

The method of claim 38, wherein the subject is identified or has been identified as a subject exhibiting one or more symptoms of the ST-elevation myocardial infarction.

### Claim 41 (depends on 38)

The method of claim 38, wherein the method comprises administering about 500 mg to about 600 mg β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, to the subject.

### Claim 42 (depends on 38)

The method of claim 38, wherein the subject is identified or has been identified as exhibiting abnormal expression of interleukin-6, interleukin-10, tumor necrosis factor-α, C-reactive protein, or any combination thereof.

### Claim 43 (depends on 38)

The method of claim 38, wherein the method comprises administering about 500 mg to about 550 mg β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, to the subject.

### Claim 44 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition comprises about 500 mg to about 600 mg of the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition comprises about 500 mg to about 550 mg of the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 39)

The method of claim 39, wherein the subject is identified or has been identified as exhibiting abnormal expression of interleukin-6, interleukin-10, tumor necrosis factor-α, C-reactive protein, or any combination thereof.

### Claim 47 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition comprises 100 mg to about 200 mg of the β-1,3/1,6-D-glucan.

### Claim 48 (depends on 39)

The method of claim 39, wherein the pharmaceutical composition comprises about 180 mg of the β-1,3/1,6-D-glucan.
